Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-1: Eloralintide in Adults With Obesity or Overweight Without Type 2 Diabetes
2025-523657-34-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Eloralintide once weekly with Placebo once weekly (2 arms). Primary endpoint: Percent change from baseline in body weight. Planned start Apr 2026; status: authorised.
02
Drugs
eloralintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2025-523657-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523657-34-00.